From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab
Grade 1
Grade 2
Grade 3
Grade 4
Grade 5
Any grade
Hypothyroidism
1
4
0
5
Liver
Diarrhea / colitis
2
Adrenal insufficiency
Rash
Peripheral motor neuropathy
Total
3
9
15